Scientific publications

Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy

Ezponda Casajús A (1), Calvo Imirizaldu M (2), de Torres Tajes JP (3), García-Baizán A (2), Castañón Álvarez E (4), Cano Rafart D (2), Vivas Pérez I (2), Bastarrika Alemañ G (2).

(1) Servicio de Radiología, Clínica Universidad de Navarra, Pamplona, Navarra, España.
(2) Servicio de Radiología, Clínica Universidad de Navarra, Pamplona, Navarra, España.
(3) Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, Navarra, España.
(4) Departamento de Oncología Médica, Clínica Universidad de Navarra, Pamplona, Navarra, España.

Magazine: Radiologia

Date: Aug 9, 2019

Radiology [SP] Pneumology Medical Oncology

OBJECTIVE:

To determine the incidence of immune-mediated adverse reactions with and without radiologic manifestations and to correlate them with the response to immunotherapy.

MATERIAL AND METHODS:

We retrospectively included 79 patients with stage IV lung carcinomas (n=24), renal carcinomas (n=11), or melanoma (n=44) treated with immunotherapy. We evaluated the occurrence of immune-mediated adverse reactions, their radiologic manifestations, and the response pattern according to the immune-related response criteria (irRC). We correlated the presence of immune-mediated adverse reactions with the response pattern.

RESULTS:

Immune-mediated adverse reactions occurred in 27.8%, being most common in patients with melanoma (40.9%). In 59.1% of patients with adverse reactions, there were radiologic manifestations such as pneumonitis, colitis, hypophysitis, thyroiditis, or myocarditis. Pneumonitis was the most common radiologic manifestation of immune-mediated adverse reactions, even in asymptomatic patients. The rate of response to immunotherapy was higher among patients who developed immune-mediated adverse reactions than in those who did not (68.2% vs. 38.6%, respectively, χ2 5.58; p=0.018). The rate of favorable responses was higher in patients with radiologic manifestations of immune-mediated adverse reactions than in those without radiologic manifestations (84.6% vs. 44.4%, respectively; p=0.023).

CONCLUSIONS:

The presence of immune-mediated adverse reactions is associated with a better response to immunotherapy. The association with a favorable response is even stronger in patients with radiologic manifestations of the immune-mediated adverse reactions. se criteria, immune-mediated adverse reactions, medical oncology (MeSH term).

CITATION  Radiologia. 2019 Aug 9. pii: S0033-8338(19)30100-6. doi: 10.1016/j.rx.2019.06.004

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra